Bibliografía del artículo
1. Fonseca FAH. Farmacocinética das estatinas. Arq Bras Cardiol 85 (Suppl 5):S9-13, 2005.
2. Xavier HT, Izar MC, Faria Neto JR, Assad MH, Rocha VZ, Sposito AC, et al. V Diretriz brasileira de dislipidemias e prevenção da aterosclerose. Arq Bras Cardiol 101(4 Supl.1):S1-22, 2013.
3. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CR, Eckel RH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 129 (Suppl 2):S1-45, 2014.
4. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64(1):102-46, 2012.
5. Nigovi B, Mornar A, Serti M. A Review of current trends and advances in analytical methods for determination of statins: chromatography and capillary electrophoresis, chromatography - the most versatile method of chemical analysis [text on the internet]. Intech: doi10.5772/48694 [update 2012; cited 2014 Aug 15]. Available from: http://www.intechopen.com/books/chromatography-the-most-versatile-method-of-chemical-analysis/a-review-of-current-trends-and-advances-in-analytical-methods-for-determination-of-statins-chromatog.
6. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot 29(12):1346-8, 1976.
7. Butterfield DA, Barone E, Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 64(3):180-6, 2011.
8. Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin. Adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 27(5):635-62, 2011.
9. Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, et al. The spectrum of statin hepatotoxicity: experience of the drug induced liver injury network. Hepatology 60(2):679-86, 2014.
10. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 349(g3743):1-10, 2014.
11. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (23 Suppl I):III 39-43, 2004.
12. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4):833-43, 2007.
13. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170.000 participants in 26 randomised trials. Lancet 376(9753):1670-81, 2010.
14. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol 73(4):518-35, 2011.
15. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769-818, 2011.
16. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AMJ, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195-207, 2008.
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170.000 participants in 26 randomised trials. Lancet 376(9753):1670-81, 2010.
18. Pedersen TR. Overview of clinical trials on calcific stenosis. Eur Heart J 10(Supplement E):E32-40, 2008.